Regulatory Insight: Germany's Psilocybin Compassionate Use Program Advances, Outpatient Coverage Under Review

Germany has implemented the European Union's first psilocybin compassionate use program, enabling patient access at OVID Clinic Berlin and the Central Institute of Mental Health (CIMH) in Mannheim. While inpatient treatment receives public insurance coverage, both sites are actively pursuing approvals for outpatient modalities. CIMH Mannheim is currently awaiting critical approval from Germany's drug regulator (BfArM) to extend public insurance coverage to outpatient psilocybin therapy, marking a significant step in EU psychedelic regulatory evolution.